Monopar Therapeutics (NASDAQ:MNPR) Price Target Raised to $40.00

Monopar Therapeutics (NASDAQ:MNPR) had its price objective upped by HC Wainwright from $22.00 to $40.00 in a report published on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock. HC Wainwright also issued estimates for Monopar Therapeutics’ FY2026 earnings at $0.70 EPS, FY2027 earnings at $2.10 EPS, FY2028 earnings at $3.04 EPS and FY2029 earnings at $3.66 EPS.

A number of other research analysts have also weighed in on MNPR. Piper Sandler started coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They issued an “overweight” rating and a $72.00 target price on the stock. Rodman & Renshaw began coverage on shares of Monopar Therapeutics in a report on Friday, October 11th. They issued a “buy” rating and a $50.00 target price for the company.

Monopar Therapeutics Trading Up 5.4 %

Monopar Therapeutics stock opened at $41.46 on Wednesday. Monopar Therapeutics has a 12 month low of $1.54 and a 12 month high of $41.94. The firm has a market cap of $252.91 million, a PE ratio of -21.05 and a beta of 1.23. The stock’s 50 day simple moving average is $24.19 and its two-hundred day simple moving average is $12.34.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.09. On average, equities research analysts forecast that Monopar Therapeutics will post -1.65 EPS for the current year.

Insiders Place Their Bets

In other Monopar Therapeutics news, CFO Karthik Radhakrishnan acquired 1,550 shares of the company’s stock in a transaction dated Monday, October 28th. The shares were acquired at an average price of $16.25 per share, for a total transaction of $25,187.50. Following the acquisition, the chief financial officer now owns 1,550 shares in the company, valued at $25,187.50. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 34.90% of the stock is owned by company insiders.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.